期刊文献+

肺腺癌患者EGFR突变与TTF-1的关系及意义研究 被引量:11

Research of relation and significance between EGFR mutations and TTF- 1 in lung adenocarcinoma
下载PDF
导出
摘要 目的分析肺腺癌患者EGFR突变与TTF-1及患者临床相关因素的相关性。方法对247例肺腺癌组织标本进行TTF-1及EGFR检测,分析两者间的相关性及临床意义。结果肺腺癌EGFR突变97例(39.27%),其中19外显子缺失突变27例(10.93%),21外显子点突变70例(28.34%);EGFR突变者均为TTF-1染色阳性,而TTF-1阴性或部分阳性者无1例有EGFR突变,EGFR突变与TTF-1表达具有明显相关性(P=0.0057);TTF-1阳性、女性、不吸烟、血清CEA异常(≥5 ng/ml),肿瘤远处转移患者EGFR突变率较高。结论肺腺癌患者EGFR突变与TTF-1呈明显正相关性,TTF-1表达情况在一定程度上可预测肺腺癌EGFR突变状况,为临床治疗决策提供有意义的线索。 Objective To analyze the relationship between EGFR mutations and TTF -1 in patients with lung adenocarcinoma.Methods 247 cases with lung adenocarcinoma were collected to detect TTF-1 and EGFR mu-tations,then to analysis the relationship between EGFR mutations and TTF-1 .Results There were 97 cases of EG-FR mutations (39.27%),including 27 cases of 1 9-exons deletion (1 0.93%)and 70 cases of 21-exons point muta-tions (L858R).The cases of EGFR mutations all had positive TTF-1 .EGFR mutation had clear correlation with the expression of TTF-1 (P=0.0057).The high risk factors of mutation were positive expression of TTF-1 ,women,no smoking and abnormal serum CEA≥5 ng/ml.Conclusion EGFR mutation is related with the positive expression of TTF-1 in patients with lung adenocarcinoma.
出处 《临床肺科杂志》 2015年第2期224-227,共4页 Journal of Clinical Pulmonary Medicine
关键词 腺癌 EGFR TTF-1 CEA adenocarcinoma EGFR TTF-1 CEA
  • 相关文献

参考文献3

二级参考文献45

  • 1Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non - small cell lung cancer search and destroy. Eur J Cancer,2006,42(1) :17 -23.
  • 2Dexter EU, Jahangir N, Kohman LJ. Resection for lung cancer in the elderly patient. Thorac Surg Clin, 2004,14 ( 2 ) : 163 - 171.
  • 3Sequist LV, Bell DW, Lynch TJ,et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non - small - cell lung cancer. J Clin Oncol,2007,25 ( 5 ) :587 - 595.
  • 4Lynch TJ,Bell DW,Sordella R,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small - cell lung cancer to gefitinib. N Engl J Med,2004,350(21) :2129 -2139.
  • 5Paez JG,Janne PA, Lee JC,et al. EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science, 2004, 304 (5676) :1497 - 1500.
  • 6Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gdhinib and erlotinib. Proc Natl Acad Sci USA, 2004,101 (36) :13306 - 13311.
  • 7Salgia R, Harpole D, Herndon JE, et al. Role of serum tumor markers CA125 and CEA in non -small cell lung cancer, Auticancer es,2001,21(2B):1241-1246.
  • 8Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353: 123-32.
  • 9Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated (INTEREST): a randomized phase Ⅲ trial. Lancet 2008, 372: 1809-18.
  • 10Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyro-sine kinase, in symptomatic patients with non-small cell lun cancer: a randomized trial. JAMA 2003, 290: 2149-58.

共引文献80

同被引文献66

  • 1毛建华,罗庆丰,刘志礼,王恒,朱粮博,龙新华,周荣平.LY294002抑制成骨肉瘤细胞U2-OS侵袭迁徙[J].实用癌症杂志,2014,29(2):123-125. 被引量:6
  • 2Sheffield BS, Bosdet IE, All RH, et al. Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer[J]. Curr oncol, 2014, 21(6): 305-308.
  • 3E1-Zammar OA, Zhang S, Katzenstein AL. Comparison of FISH, PCR, and try in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features [ J ]. Diagn mol pathol, 2009, 18 (3) : 133-137.
  • 4Ao MH, Zhang H, Sakowski L, et al. The utility of a novel triple marker(combination of TYF1, napsin A, and p40) in the sub- classification of non-small cell lung cancer [ J ]. Hum pathol, 2014, 45(5) : 926-934.
  • 5Sun PL, Seol H, Lee HJ, et al. High incidence of EGFR muta- tions in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EG- FR/TFF-1 expressions, and clinical features [ J ]. J Thorac Oncol, 2012, 7(2): 323-330.
  • 6Peterson MR, Piao Z, Bazhenova LA, et al. Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations[ J]. Appl Immuno- histochem lVlol Morphol, 2007, 15(3) : 242-247.
  • 7Yatabe Y,Takahashi T, Mitsudomi T. Epidermal growth factor re- ceptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer [ J ]. Cancer Res, 2008, 68(7) :2106-2111.
  • 8Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors : guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology [ J ]. J Mol Di- an. 2013_ 15(4") ,415-453.
  • 9奉水东,谭红专.肺癌EGFR基因突变检测方法的研究进展[J].中国肺癌杂志,2008,11(3):462-464. 被引量:14
  • 10肿瘤标志物的临床应用建议[J].中华检验医学杂志,2012,35(2):103-116. 被引量:92

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部